Insight Molecular DiagnosticsIMDX +0.81%49 Days Inventory is 2,222.21 as of Mar. 2026, which is 1919% above its 10-year median of 110.04. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 177 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks worse than 83.62% on this metric.
The historical rank and industry rank for Insight Molecular Diagnostics's Days Inventory or its related term are showing as below:
IMDX'
s Days Inventory Range Over the Past 10 Years
Min: 88.91 Med: 110.04 Max: 188.54
Current: 188.54
During the past 13 years, Insight Molecular Diagnostics's highest Days Inventory was 188.54. The lowest was 88.91. And the median was 110.04.
IMDX's Days Inventory is ranked worse than 83.62% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: 70.8
vs IMDX: 188.54
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Insight Molecular Diagnostics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Insight Molecular Diagnostics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 12.94.
Insight Molecular Diagnostics (NAS:IMDX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Insight Molecular Diagnostics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Insight Molecular Diagnostics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Insight Molecular Diagnostics Days Inventory Related Terms
Insight Molecular Diagnostics Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Days Inventory Chart
IMDX vs BDSX, XGN, FONR: Days Inventory Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Days Inventory of 2,222.21 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Insight Molecular Diagnostics and its competitors. This is 1919% above median its historical median of 110.04. Over the past decade, Insight Molecular Diagnostics' Days Inventory has ranged from 88.91 to 188.54. According to the industry distribution chart, Insight Molecular Diagnostics ranks #148 out of 177 companies in the Medical Diagnostics & Research industry, placing it in the top 83.6%.
Is Insight Molecular Diagnostics' Days Inventory too high?
Insight Molecular Diagnostics' current Days Inventory of 2,222.21 is 1919% above median its 10-year median of 110.04. Over the past 10 years, this metric has ranged from a low of 88.91 to a high of 188.54. The Medical Diagnostics & Research industry median Days Inventory is 70.80. Insight Molecular Diagnostics' value of 2,222.21 is 3038.7% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #148 out of 177 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Days Inventory compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #148 out of 177 companies for Days Inventory. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median Days Inventory is 70.80. Insight Molecular Diagnostics' value of 2,222.21 is 3038.7% above this benchmark. Historically, Insight Molecular Diagnostics' own Days Inventory has ranged from 88.91 to 188.54 over the past decade. While the company's 10-year median is 110.04 vs. the industry median of 70.80, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 70.80, based on 177 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Days Inventory of 2,222.21 is 3038.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 70.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Days Inventory is 2,222.21, which is 1919% above median its own 10-year median of 110.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.63 — trading 346.4% above its estimated fair value. The current Days Inventory is 2,222.21, which is 1919% above median its 10-year median of 110.04 and 3038.7% above the Medical Diagnostics & Research industry median of 70.80. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Days Inventory is 2,222.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.63 is trading 346.4% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Days Inventory: 2,222.21 (1919% above median its 10-year median of 110.04)
GF Value™: $1.26 vs. price of $5.63 (346.4% above fair value)
Industry Position: 3038.7% above the Medical Diagnostics & Research median (#148 of 177)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
